ARL6IP4

Summary

ARL6IP4 (ARF like GTPase 6 interacting protein 4, HGNC:18076) is a protein-coding gene on chromosome 12q24.31, encoding ADP-ribosylation factor-like protein 6-interacting protein 4 (Q66PJ3). Involved in modulating alternative pre-mRNA splicing with either 5’ distal site activation or preferential use of 3’ proximal site.

Enables identical protein binding activity. Predicted to be involved in RNA splicing. Predicted to be located in nucleus.

Source: NCBI Gene 51329 — RefSeq curated summary.

At a glance

• GWAS associations: 6
• Clinical variants (ClinVar): 96 total
• MANE Select transcript: NM_018694

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:18076
Approved symbol	ARL6IP4
Name	ARF like GTPase 6 interacting protein 4
Location	12q24.31
Locus type	gene with protein product
Status	Approved
Aliases	SR-25, SRp25, SFRS20, SRrp37
Ensembl gene	ENSG00000182196
Ensembl biotype	protein_coding
OMIM	607668
Entrez	51329

Gene structure

Transcript identifiers

Ensembl transcripts: 84 — 75 protein_coding, 6 retained_intron, 2 nonsense_mediated_decay, 1 protein_coding_CDS_not_defined

ENST00000315580, ENST00000357866, ENST00000392433, ENST00000392435, ENST00000412505, ENST00000413381, ENST00000426960, ENST00000439686, ENST00000442210, ENST00000453766, ENST00000454885, ENST00000456762, ENST00000536073, ENST00000536502, ENST00000539576, ENST00000539770, ENST00000540382, ENST00000540708, ENST00000542099, ENST00000543566, ENST00000853809, ENST00000853810, ENST00000853811, ENST00000853812, ENST00000853813, ENST00000853814, ENST00000853815, ENST00000853816, ENST00000853817, ENST00000853818, ENST00000853819, ENST00000853820, ENST00000853821, ENST00000853822, ENST00000853823, ENST00000853824, ENST00000853825, ENST00000853826, ENST00000853827, ENST00000853828, ENST00000853829, ENST00000853830, ENST00000853831, ENST00000853832, ENST00000853833, ENST00000853834, ENST00000853835, ENST00000853836, ENST00000853837, ENST00000853838, ENST00000853839, ENST00000853840, ENST00000853841, ENST00000853842, ENST00000853843, ENST00000853844, ENST00000853845, ENST00000853846, ENST00000853847, ENST00000853848, ENST00000853849, ENST00000853850, ENST00000853851, ENST00000853852, ENST00000853853, ENST00000853854, ENST00000853855, ENST00000925030, ENST00000925031, ENST00000925032, ENST00000925033, ENST00000925034, ENST00000925035, ENST00000925036, ENST00000925037, ENST00000925038, ENST00000925039, ENST00000925040, ENST00000962562, ENST00000962563, ENST00000962564, ENST00000962565, ENST00000962566, ENST00000962567

RefSeq mRNA: 32 — MANE Select: NM_018694 NM_001002251, NM_001278378, NM_001278379, NM_001278380, NM_001400281, NM_001400282, NM_001400283, NM_001400284, NM_001400285, NM_001400300, NM_001400301, NM_001400302, NM_001400303, NM_001400304, NM_001400305, NM_001400306, NM_001400307, NM_001400308, NM_001400309, NM_001400310, NM_001400311, NM_001400312, NM_001400313, NM_001400314, NM_001400315, NM_001400316, NM_001400317, NM_001400318, NM_001400319, NM_001400320, NM_016638, NM_018694

CCDS: CCDS31923, CCDS45004, CCDS53843, CCDS61273, CCDS91764, CCDS91765

Canonical transcript exons

ENST00000315580 — 6 exons

Exon	Start	End
ENSE00001254056	122981571	122981879
ENSE00001641411	122982620	122982909
ENSE00003638724	122981957	122982074
ENSE00003672941	122981129	122981299
ENSE00003785915	122982469	122982538
ENSE00003917601	122980681	122980745

Expression profiles

Bgee: expression breadth ubiquitous, 134 present calls, max score 99.06.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 128.2455 / max 671.0581, expressed in 1827 samples.

FANTOM5 promoters (9 alternative TSS)

Promoter ID	TPM avg	Samples expressed
128554	119.1181	1827
128550	2.6225	1094
128556	2.2619	1319
128551	1.3562	734
128555	0.8008	448
128553	0.7799	490
128552	0.5816	358
128557	0.4740	154
128558	0.2505	85

Top tissues by expression

134 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
pituitary gland	UBERON:0000007	99.06	gold quality
adenohypophysis	UBERON:0002196	99.02	gold quality
amygdala	UBERON:0001876	98.99	gold quality
temporal lobe	UBERON:0001871	98.98	gold quality
fundus of stomach	UBERON:0001160	98.90	gold quality
popliteal artery	UBERON:0002250	98.90	gold quality
tibial artery	UBERON:0007610	98.90	gold quality
muscle layer of sigmoid colon	UBERON:0035805	98.90	gold quality
esophagogastric junction muscularis propria	UBERON:0035841	98.90	gold quality
right frontal lobe	UBERON:0002810	98.88	gold quality
lower esophagus muscularis layer	UBERON:0035833	98.88	gold quality
prostate gland	UBERON:0002367	98.87	gold quality
anterior cingulate cortex	UBERON:0009835	98.87	gold quality
lower esophagus	UBERON:0013473	98.87	gold quality
apex of heart	UBERON:0002098	98.86	gold quality
body of stomach	UBERON:0001161	98.84	gold quality
spleen	UBERON:0002106	98.84	gold quality
right hemisphere of cerebellum	UBERON:0014890	98.84	gold quality
left coronary artery	UBERON:0001626	98.82	gold quality
left ovary	UBERON:0002119	98.82	gold quality
left adrenal gland cortex	UBERON:0035825	98.82	gold quality
right coronary artery	UBERON:0001625	98.81	gold quality
hypothalamus	UBERON:0001898	98.80	gold quality
dorsolateral prefrontal cortex	UBERON:0009834	98.80	gold quality
endocervix	UBERON:0000458	98.79	gold quality
body of pancreas	UBERON:0001150	98.79	gold quality
ascending aorta	UBERON:0001496	98.79	gold quality
thoracic aorta	UBERON:0001515	98.79	gold quality
frontal cortex	UBERON:0001870	98.79	gold quality
substantia nigra	UBERON:0002038	98.79	gold quality

Single-cell (SCXA)

Detected in 3 experiment(s), a significant marker in 2.

Experiment	Marker?	Max mean expression
E-ANND-3	yes	12.98
E-HCAD-13	yes	7.36
E-MTAB-6142	no	314.09

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

6 targeting ARL6IP4, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-130B-5P	99.83	68.50	1888
HSA-MIR-6842-5P	99.80	67.54	1587
HSA-MIR-7110-5P	99.80	67.84	1712
HSA-MIR-4251	99.40	69.19	3363
HSA-MIR-210-5P	98.57	64.37	832
HSA-MIR-4640-5P	97.42	66.33	1543

Cross-species orthologs

4 orthologs

Organism	Symbol	Gene ID
danio_rerio	arl6ip4	ENSDARG00000105036
mus_musculus	Arl6ip4	ENSMUSG00000029404
rattus_norvegicus	Arl6ip4	ENSRNOG00000001080
drosophila_melanogaster	CG18428	FBGN0039149

Protein

Protein identifiers

ADP-ribosylation factor-like protein 6-interacting protein 4 — Q66PJ3 (reviewed: Q66PJ3)

Alternative names: HSP-975, HSVI-binding protein, SR-15, SRp25, Splicing factor SRrp37

All UniProt accessions (9): Q66PJ3, A0A0A0MTG7, A0A0C4DG62, A0A0C4DH18, A0A8C8KBE9, F5GYV5, F8WCT1, F8WEP2, H7BZV4

UniProt curated annotations — full annotation on UniProt →

Function. Involved in modulating alternative pre-mRNA splicing with either 5’ distal site activation or preferential use of 3’ proximal site. In case of infection by Herpes simplex virus (HSVI), may act as a splicing inhibitor of HSVI pre-mRNA.

Subunit / interactions. Interacts with ARL6. Interacts with ZCCHC17. Interacts with SRSF2.

Subcellular location. Nucleus. Nucleolus. Nucleus speckle.

Tissue specificity. Isoforms 3 and 7 were identified in brain, pancreas, prostate, and testis, but little or no message could be detected in other tissues.

Induction. In case of Herpes simplex virus (HSVI)-binding to cells.

Similarity. Belongs to the ARL6IP4 family.

Isoforms (10)

UniProt ID	Names	Canonical?
Q66PJ3-8	8	yes
Q66PJ3-1	1
Q66PJ3-2	2
Q66PJ3-3	3
Q66PJ3-4	4
Q66PJ3-5	5
Q66PJ3-6	6
Q66PJ3-7	7, SRrp37-2
Q66PJ3-9	9
Q66PJ3-10	10

RefSeq proteins (32): NP_001002251, NP_001265307, NP_001265308, NP_001265309, NP_001387210, NP_001387211, NP_001387212, NP_001387213, NP_001387214, NP_001387229, NP_001387230, NP_001387231, NP_001387232, NP_001387233, NP_001387234, NP_001387235, NP_001387236, NP_001387237, NP_001387238, NP_001387239, NP_001387240, NP_001387241, NP_001387242, NP_001387243, NP_001387244, NP_001387245, NP_001387246, NP_001387247, NP_001387248, NP_001387249, NP_057722, NP_061164* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR019532	Nucl_RNA-splicing_assoc_SR-25	Family

Pfam: PF10500

UniProt features (20 total): splice variant 8, compositionally biased region 4, modified residue 3, chain 1, region of interest 1, sequence variant 1, sequence conflict 1, cross-link 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q66PJ3-F1	58.86	0.00

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Post-translational modifications (4): 55, 148, 182, 199

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 96 (showing top): MULLIGHAN_NPM1_SIGNATURE_3_UP, TGCGCANK_UNKNOWN, GROSS_HYPOXIA_VIA_ELK3_UP, TCF11_01, GOBP_RNA_SPLICING, TCCAGAT_MIR5165P, GOCC_NUCLEAR_SPECK, GOCC_NUCLEAR_BODY, GOCC_RIBONUCLEOPROTEIN_GRANULE, GOCC_NUCLEOLUS, chr12q24, CASORELLI_ACUTE_PROMYELOCYTIC_LEUKEMIA_DN, MULLIGHAN_NPM1_MUTATED_SIGNATURE_1_UP, MARTENS_TRETINOIN_RESPONSE_DN, BYSTRYKH_HEMATOPOIESIS_STEM_CELL_QTL_TRANS

GO Biological Process (2): mRNA processing (GO:0006397), RNA splicing (GO:0008380)

GO Molecular Function (3): RNA binding (GO:0003723), protein binding (GO:0005515), identical protein binding (GO:0042802)

GO Cellular Component (3): nucleus (GO:0005634), nucleolus (GO:0005730), nuclear speck (GO:0016607)

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
RNA processing	2
mRNA metabolic process	1
nucleic acid binding	1
binding	1
protein binding	1
intracellular membrane-bounded organelle	1
nuclear lumen	1
intracellular membraneless organelle	1
nuclear ribonucleoprotein granule	1

Protein interactions and networks

STRING

910 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
ARL6IP4	ZFYVE1	Q9HBF4	512
ARL6IP4	TMEM11	P17152	474
ARL6IP4	SUB1	P53999	452
ARL6IP4	OGFOD2	Q6N063	449
ARL6IP4	PNISR	Q8TF01	426
ARL6IP4	THRAP3	Q9Y2W1	418
ARL6IP4	PPIA	P05092	415
ARL6IP4	ATAD2B	Q9ULI0	412
ARL6IP4	ELP3	Q9H9T3	407
ARL6IP4	RRP36	Q96EU6	400
ARL6IP4	SNX19	Q92543	391
ARL6IP4	MPHOSPH9	Q99550	384
ARL6IP4	ENSA	O43768	383
ARL6IP4	ABCB9	Q9NP78	370
ARL6IP4	DGKI	O75912	367

IntAct

66 interactions, top by confidence:

A	B	Type	Score
PIK3CA	PIK3R2	psi-mi:“MI:0914”(association)	0.900
CFTR	ESYT2	psi-mi:“MI:0914”(association)	0.710
SRPK2	ARL6IP4	psi-mi:“MI:0217”(phosphorylation reaction)	0.690
CFTR	HAX1	psi-mi:“MI:0914”(association)	0.610
ARL6IP4	SRPK1	psi-mi:“MI:0217”(phosphorylation reaction)	0.590
ARL6IP4	tax	psi-mi:“MI:0915”(physical association)	0.490
tax	ARL6IP4	psi-mi:“MI:0915”(physical association)	0.490
CFTR	CNOT1	psi-mi:“MI:0914”(association)	0.480
CPSF6	DDX39A	psi-mi:“MI:0914”(association)	0.480
ARL6IP4	HNRNPM	psi-mi:“MI:0915”(physical association)	0.400
ARL6IP4	KRT18	psi-mi:“MI:0915”(physical association)	0.400
ARL6IP4	ARL6IP4	psi-mi:“MI:0915”(physical association)	0.370
TMEM132A	WWP2	psi-mi:“MI:0914”(association)	0.350
Ppp6c	PLEKHG3	psi-mi:“MI:0914”(association)	0.350
DVL2	NBAS	psi-mi:“MI:0914”(association)	0.350
Xpo1	IFT56	psi-mi:“MI:0914”(association)	0.350
KIE-1	GTPBP10	psi-mi:“MI:0914”(association)	0.350
Mecom	ESYT2	psi-mi:“MI:0914”(association)	0.350
	AP3B1	psi-mi:“MI:0914”(association)	0.350
GAB1	JUP	psi-mi:“MI:0914”(association)	0.350
DIPK2A	C11orf98	psi-mi:“MI:0914”(association)	0.350
BMI1	MEIS3P1	psi-mi:“MI:0914”(association)	0.350
RYBP	FAM186A	psi-mi:“MI:0914”(association)	0.350
SRPK2	SNRPGP15	psi-mi:“MI:0914”(association)	0.350
CEP170	FAM171A2	psi-mi:“MI:0914”(association)	0.350
POC5	PDHX	psi-mi:“MI:0914”(association)	0.350
SHANK3	IGKV3D-15	psi-mi:“MI:0914”(association)	0.350
SNRPA	DDX39A	psi-mi:“MI:0914”(association)	0.350

BioGRID (162): ARL6IP4 (Two-hybrid), ARL6IP4 (Two-hybrid), ARL6IP4 (Two-hybrid), ARL6IP4 (Two-hybrid), THAP1 (Two-hybrid), JMJD6 (Affinity Capture-MS), CSNK2A2 (Affinity Capture-MS), ZRANB2 (Affinity Capture-MS), EIF3J (Affinity Capture-MS), SRPK1 (Affinity Capture-MS), CCDC9 (Affinity Capture-MS), C17orf85 (Affinity Capture-MS), ZC3H14 (Affinity Capture-MS), USP7 (Affinity Capture-MS), GPALPP1 (Affinity Capture-MS)

ESM2 similar proteins: A0A1S3XQD6, A0A1S4AX27, A1A5I1, A2AR02, A6QLS2, B0BN49, O35986, O55035, O95218, P30189, P30414, P30415, Q19QU3, Q27450, Q28EE8, Q2HJC9, Q3B7G7, Q3KPW4, Q4P4G8, Q4V8I5, Q4V9W2, Q502P0, Q505I5, Q5BKY9, Q5F4A9, Q5R580, Q5R8J6, Q5RJP9, Q5VTL8, Q5XHJ5, Q5ZLM8, Q5ZLX5, Q66PJ3, Q6AXY7, Q6C1V6, Q6NQD9, Q6P7Y3, Q6ZUT1, Q7L4I2, Q80SY5

Diamond homologs: Q3KPW4, Q4V8I5, Q502P0, Q5F4A9, Q66PJ3, Q9JM93

SIGNOR signaling

1 interactions.

A	Effect	B	Mechanism
SGK3	“down-regulates activity”	ARL6IP4	phosphorylation

Enriched among interaction partners

Reactome pathways and GO biological processes over-represented among this gene’s 84 IntAct physical interaction partners (hypergeometric vs the genome-wide background, BH-FDR, gene-set size 15–500, ranked by fold). A functional readout of the neighbourhood — distinct from this gene’s own memberships above, and biased toward well-studied / hub proteins, so read it as themes rather than proof.

Reactome pathways:

Pathway	Partners	Fold	FDR
Constitutive Signaling by EGFRvIII	5	64.9×	8e-07
Signaling by ERBB2 ECD mutants	5	61.1×	9e-07
Tie2 Signaling	5	54.6×	1e-06
Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants	5	51.9×	1e-06
Signaling by phosphorylated juxtamembrane, extracellular and kinase domain KIT mutants	5	47.2×	2e-06
Signaling by FGFR3 in disease	5	45.1×	2e-06
Signaling by ERBB2 KD Mutants	5	38.5×	5e-06
Downstream signal transduction	5	34.6×	8e-06

GO biological processes:

GO term	Partners	Fold	FDR
mRNA splicing, via spliceosome	10	13.3×	2e-06
RNA splicing	8	10.2×	3e-04
mRNA processing	7	8.0×	6e-03

Disease & clinical

Clinical variants and AI predictions

ClinVar

96 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	84
Likely benign	4
Benign	0

Top pathogenic / likely-pathogenic (0)

SpliceAI

1183 predictions. Top by Δscore:

Variant	Effect	Δscore
12:122981864:G:GT	donor_gain	1.0000
12:122981870:G:GT	donor_gain	1.0000
12:122981955:A:AG	acceptor_gain	1.0000
12:122981956:G:GG	acceptor_gain	1.0000
12:122982113:G:GT	donor_gain	1.0000
12:122980383:GTC:G	donor_gain	0.9900
12:122981227:A:T	donor_gain	0.9900
12:122981241:G:GT	donor_gain	0.9900
12:122981875:CCCAG:C	donor_loss	0.9900
12:122981876:CCAGG:C	donor_loss	0.9900
12:122981877:CAG:C	donor_loss	0.9900
12:122981878:AGGT:A	donor_loss	0.9900
12:122981879:GGT:G	donor_loss	0.9900
12:122981881:T:G	donor_loss	0.9900
12:122981956:GTC:G	acceptor_gain	0.9900
12:122981956:GTCC:G	acceptor_gain	0.9900
12:122981956:GTCCT:G	acceptor_gain	0.9900
12:122982070:ACCAG:A	donor_loss	0.9900
12:122982071:CCAG:C	donor_loss	0.9900
12:122982072:CAG:C	donor_loss	0.9900
12:122982073:AGGT:A	donor_loss	0.9900
12:122982074:GG:G	donor_loss	0.9900
12:122982075:G:GC	donor_loss	0.9900
12:122981226:G:GT	donor_gain	0.9800
12:122981242:A:T	donor_gain	0.9800
12:122981856:C:G	donor_gain	0.9800
12:122982047:T:TA	donor_loss	0.9800
12:122982048:G:GA	donor_loss	0.9800
12:122982465:CCAG:C	acceptor_loss	0.9800
12:122982466:CA:C	acceptor_loss	0.9800

AlphaMissense

2664 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
12:122981998:C:T	P355S	0.999
12:122981999:C:A	P355H	0.998
12:122982005:C:T	T357I	0.998
12:122982018:G:C	W361C	0.998
12:122982018:G:T	W361C	0.998
12:122981997:G:C	K354N	0.997
12:122981997:G:T	K354N	0.997
12:122982002:T:C	M356T	0.997
12:122982009:G:C	K358N	0.997
12:122982009:G:T	K358N	0.997
12:122982016:T:A	W361R	0.997
12:122982016:T:C	W361R	0.997
12:122981973:G:C	Q346H	0.996
12:122981973:G:T	Q346H	0.996
12:122981993:T:C	M353T	0.996
12:122981994:G:A	M353I	0.996
12:122981994:G:C	M353I	0.996
12:122981994:G:T	M353I	0.996
12:122981998:C:A	P355T	0.996
12:122981999:C:G	P355R	0.996
12:122981989:G:C	A352P	0.995
12:122981995:A:G	K354E	0.995
12:122982478:G:C	K383N	0.995
12:122982478:G:T	K383N	0.995
12:122982499:G:C	E390D	0.995
12:122982499:G:T	E390D	0.995
12:122981981:G:C	R349P	0.994
12:122982498:A:T	E390V	0.993
12:122982647:T:C	F413L	0.993
12:122982649:C:A	F413L	0.993

dbSNP variants (sampled 300 via entrez): RS1000828804 (12:122983190 G>A), RS1001513226 (12:122980630 C>A,T), RS1002151142 (12:122979743 G>C), RS1002178266 (12:122978285 C>T), RS1002217306 (12:122980770 C>A,G,T), RS1002250193 (12:122979435 T>C), RS1002601013 (12:122981477 C>A,G,T), RS1004976175 (12:122980761 C>A,G,T), RS1005427244 (12:122982847 C>G), RS1005540244 (12:122983095 C>T), RS1005844496 (12:122982352 A>C,G), RS1005949809 (12:122979380 G>C), RS1006848035 (12:122983275 G>C), RS1007774412 (12:122981915 C>G,T), RS1008443750 (12:122980133 A>G)

Disease associations

OMIM: gene MIM:607668 | disease phenotypes:

GenCC curated gene-disease

Mondo (0):

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

6 associations (top):

Study	Trait	p-value
GCST002149_20	Schizophrenia	2.000000e-08
GCST002539_19	Schizophrenia	2.000000e-14
GCST004521_72	Autism spectrum disorder or schizophrenia	8.000000e-12
GCST006803_10	Schizophrenia	6.000000e-16
GCST007277_17	Tourette syndrome	2.000000e-06
GCST010703_43	Brain morphology (MOSTest)	1.000000e-08

EFO canonical traits (1, from GWAS)

EFO ID	Trait name
EFO:0004346	neuroimaging measurement

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

35 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
sodium arsenite	decreases expression, increases abundance, increases expression	4
Air Pollutants	affects cotreatment, increases abundance, increases expression, affects expression	2
Arsenic	decreases expression, increases abundance, increases expression	2
Ozone	affects cotreatment, increases expression, increases abundance, affects expression	2
FR900359	affects phosphorylation	1
bisphenol F	affects cotreatment, increases expression	1
triphenyl phosphate	affects expression	1
alpha-pinene	increases expression, increases abundance, affects cotreatment	1
beta-lapachone	decreases expression	1
cobaltous chloride	decreases expression	1
methacrylaldehyde	increases expression, increases abundance, affects cotreatment	1
licochalcone B	increases expression	1
Acetaminophen	decreases expression	1
Acrolein	affects cotreatment, increases expression, increases abundance	1
Atrazine	increases expression	1
Benzo(a)pyrene	increases methylation	1
Caffeine	affects phosphorylation	1
Dexamethasone	affects cotreatment, increases expression	1
Enzyme Inhibitors	increases O-linked glycosylation, decreases activity	1
Indomethacin	affects cotreatment, increases expression	1
Ivermectin	decreases expression	1
Methotrexate	affects response to substance	1
Phthalic Acids	decreases methylation	1
Ribonucleotides	affects binding	1
Selenium	increases expression	1
Smoke	decreases expression	1
Valproic Acid	increases methylation	1
Vitamin E	increases expression	1
1-Methyl-3-isobutylxanthine	affects cotreatment, increases expression	1
7,8-Dihydro-7,8-dihydroxybenzo(a)pyrene 9,10-oxide	increases expression	1

Cellosaurus cell lines

1 cell lines: 1 transformed cell line

First 10 cell lines (id-ordered, not curated):

Cellosaurus	Name	Category	Sex
CVCL_B2S6	Abcam HEK293T ARL6IP4 KO	Transformed cell line	Female

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.